Literature DB >> 32071506

Association Between Serum Testosterone and Serum PSA Among Men With and Without Partial Androgen Deficiency.

A Shukla1, B Sharda2, S Sharma3, S Bhardwaj1, U Kailash4, R Kalani1, L Satyanarayana4, A Shrivastava4.   

Abstract

Serum prostatic specific antigen (PSA) and serum testosterone levels share an undefined relationship with each other, with many conflicting studies showing both positive and negative correlation between them. Our aim was to assess association between serum PSA and serum testosterone in healthy men with normal testosterone levels and men with partial androgen deficiency (PADAM). A cross sectional study was conducted at a teaching hospital setting where serum testosterone and aging male symptom scale (AMS) scores along with PSA were studied in 255 men (> 50 years) with and without PADAM. Mean total testosterone and serum PSA was 9.35 ± 1.33 nmol/L, 1.96 ± 0.76 ng/mL in males with PADAM and 15.30 ± 1.95 nmol/L, 1.85 ± 0.73 ng/mL respectively in males without PADAM. No significant relationship was observed between serum PSA and serum testosterone levels among healthy males irrespective of PADAM in the study population. We suggest, there is no need to adjust PSA values for biopsy decisions according to testosterone levels. © Association of Clinical Biochemists of India 2018.

Entities:  

Keywords:  Aging males; PADAM; PSA; Testosterone

Year:  2018        PMID: 32071506      PMCID: PMC6995465          DOI: 10.1007/s12291-018-0785-3

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  29 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis.

Authors:  A Tsujimura; K Matsumiya; Y Miyagawa; T Takao; K Fujita; S Takada; M Koga; A Iwasa; M Takeyama; A Okuyama
Journal:  Int J Impot Res       Date:  2005 May-Jun       Impact factor: 2.896

Review 3.  Testosterone and prostate cancer: an historical perspective on a modern myth.

Authors:  Abraham Morgentaler
Journal:  Eur Urol       Date:  2006-07-27       Impact factor: 20.096

Review 4.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

5.  Serum PSA as a predictor of testosterone deficiency.

Authors:  Giulia Rastrelli; Giovanni Corona; Linda Vignozzi; Elisa Maseroli; Antonio Silverii; Matteo Monami; Edoardo Mannucci; Gianni Forti; Mario Maggi
Journal:  J Sex Med       Date:  2013-07-16       Impact factor: 3.802

6.  Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.

Authors:  A T Guay; J B Perez; W A Fitaihi; M Vereb
Journal:  Endocr Pract       Date:  2000 Mar-Apr       Impact factor: 3.443

Review 7.  Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

Authors:  Abraham Morgentaler; Abdulmaged M Traish
Journal:  Eur Urol       Date:  2008-09-24       Impact factor: 20.096

8.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009

9.  Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men.

Authors:  Bo Sung Shin; Eu Chang Hwang; Chang Min Im; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  Korean J Urol       Date:  2010-12-21

10.  Is there an association between serum prostate-specific antigen values and serum testosterone levels in healthy men?

Authors:  Mahmoud Mustafa; Rahim Horuz; Metin Celik; Akif Kucukcan
Journal:  Korean J Urol       Date:  2014-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.